Undifferentiated Pleomorphic Sarcoma Overview

Save information for later
Sign Up

Learn About Undifferentiated Pleomorphic Sarcoma

What is the definition of Undifferentiated Pleomorphic Sarcoma?
Undifferentiated pleomorphic sarcoma (UPS), also known as malignant fibrous histiocytoma, is a rare, aggressive soft tissue or bone cancer that usually occurs in the arms or legs in the sixth or seventh decade of life.
What are the symptoms of Undifferentiated Pleomorphic Sarcoma?
Symptoms of undifferentiated pleomorphic sarcoma may include the presence of a mostly painless, rapidly enlarging nodule in the lower extremities (especially the thigh), upper arms, head and neck, retroperitoneum, viscera, distal or proximal femur (upper leg), proximal tibia (lower leg), or humerus (upper arm). Additional symptoms of undifferentiated pleomorphic sarcoma may include pain, swelling, malaise, lack of appetite, constipation, fever, and weight loss.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Undifferentiated Pleomorphic Sarcoma?
Treatment for undifferentiated pleomorphic sarcoma depends on the location but may include surgery, radiation therapy, chemotherapy (ifosfamide, trabectedin, dacarbazine, and pazopanib), targeted therapy, and immunotherapy.
Who are the top Undifferentiated Pleomorphic Sarcoma Local Doctors?
Richard F. Riedel
Elite in Undifferentiated Pleomorphic Sarcoma
Dr. Richard F. Riedel
Oncology
Elite in Undifferentiated Pleomorphic Sarcoma
Dr. Richard F. Riedel
Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Riedel is an Oncologist in Durham, North Carolina. Dr. Riedel is rated as an Elite provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma. Dr. Riedel is currently accepting new patients.

Mark A. Dickson
Elite in Undifferentiated Pleomorphic Sarcoma
Dr. Mark A. Dickson
Hematology Oncology | Hematology | Oncology
Elite in Undifferentiated Pleomorphic Sarcoma
Dr. Mark A. Dickson
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Dickson is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Dickson is rated as an Elite provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Endoscopy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Undifferentiated Pleomorphic Sarcoma
Dr. William D. Tap
Hematology Oncology | Hematology | Oncology
Elite in Undifferentiated Pleomorphic Sarcoma
Dr. William D. Tap
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Tap is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Tap is rated as an Elite provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization.

View All Doctors
What are the latest Undifferentiated Pleomorphic Sarcoma Clinical Trials?
A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 3

Summary: This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Enrollment Status: Recruiting
Publish Date: November 13, 2025
Intervention Type: Biological
Study Phase: Phase 1

Summary: This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.

View All Clinical Trials